Holen Sie sich die Stockscreener-App
11.45
3.17%
-0.375
Handel nachbörslich:
11.45
0.005
+0.04%
Schlusskurs vom Vortag:
$11.82
Offen:
$11.77
24-Stunden-Volumen:
530.17K
Relative Volume:
0.39
Marktkapitalisierung:
$999.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-185.15M
KGV:
-5.651
EPS:
-2.0253
Netto-Cashflow:
$-148.72M
1W Leistung:
-2.18%
1M Leistung:
-8.51%
6M Leistung:
-55.50%
1J Leistung:
+122.67%
1-Tages-Spanne:
$11.37
$11.87
1-Wochen-Bereich:
$11.02
$12.53
52-Wochen-Spanne:
$4.47
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
11.45 | 1.05B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 12,500 Shares of Stock - MarketBeat
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals director Cyrus Harmon sells $291k in stock - Investing.com
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Cash Flow - TradingKey
OLMA|Olema Pharmaceuticals Inc|Price:11.470|Chg%:-0.540 - TradingKey
OLMA|Olema Pharmaceuticals Inc|Price:12.020|Chg%:+0.320 - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Form 144 Olema Pharmaceuticals For: 24 July By Investing.com - Investing.com South Africa
Olema Pharmaceuticals launches recruitment drive for medical science liaison role - Traders Union
OLMA (NASDAQ: OLMA) insider plans Rule 144 sale of 12,500 common shares - Stock Titan
Siren L.L.C. Boosts Stake in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9%Here's Why - MarketBeat
Olema Pharmaceuticals appoints Brad Lanoue as vice president of market access - Traders Union
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell" - MarketBeat
Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Price to book forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary - Quartr
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to sales forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Pharmaceuticals (OLMA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesInvestor Earnings Call - dars.gov.et
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals (OLMA) Q1 2026 Earnings: EPS Beats Estimates Amid Continued R&D ProgressEnergy Earnings Report - DonanımHaber
Olema Pharmaceuticals opens director clinical science role to advance cancer trial programs - Traders Union
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index InclusionHas The Bull Case Changed? - simplywall.st
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Yahoo Finance
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2500 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2000 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell 3000E Growth Benchmark - marketscreener.com
Olema Pharmaceuticals (OLMA) Holds Steady Near Support Amid Minor DeclineUp Down Volume - dars.gov.et
Olema Pharmaceuticals (OLMA) Holds Steady Near Support After Minor DeclineHidden Order - dars.gov.et
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA) - TradingView
OLMA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Olema (NASDAQ: OLMA) awards director 29,500 stock options - Stock Titan
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants - Stock Titan
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51 - Stock Titan
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Olema Pharmaceuticals Inc-Aktie (OLMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director |
Jul 23 '26 |
Sale |
11.58 |
12,500 |
144,738 |
715,270 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):